Analysts Offer Predictions for ELEV Q1 Earnings

Elevation Oncology, Inc. (NASDAQ:ELEV) – Equities research analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for Elevation Oncology in a research note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst A. Berens forecasts that the company will post earnings per share of ($0.23) for the quarter. The consensus estimate for Elevation Oncology’s current full-year earnings is ($0.84) per share. Leerink Partnrs also issued estimates for Elevation Oncology’s Q3 2025 earnings at ($0.21) EPS and Q4 2025 earnings at ($0.21) EPS.

Elevation Oncology (NASDAQ:ELEV) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.02).

ELEV has been the topic of several other reports. HC Wainwright restated a “buy” rating and issued a $6.00 price target on shares of Elevation Oncology in a research note on Tuesday, January 14th. Stephens reaffirmed an “overweight” rating and set a $5.00 target price on shares of Elevation Oncology in a report on Friday, December 6th. JMP Securities reiterated a “market outperform” rating and issued a $7.00 price target on shares of Elevation Oncology in a research note on Thursday, December 19th. Finally, William Blair initiated coverage on Elevation Oncology in a research note on Friday, January 3rd. They set an “outperform” rating on the stock. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $7.20.

Elevation Oncology Stock Performance

ELEV stock opened at $0.67 on Friday. Elevation Oncology has a fifty-two week low of $0.50 and a fifty-two week high of $5.83. The company has a current ratio of 17.77, a quick ratio of 17.77 and a debt-to-equity ratio of 0.45. The business’s fifty day moving average price is $0.65 and its two-hundred day moving average price is $0.79.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. SG Americas Securities LLC acquired a new position in Elevation Oncology in the 3rd quarter worth about $28,000. JPMorgan Chase & Co. increased its holdings in Elevation Oncology by 175.9% in the third quarter. JPMorgan Chase & Co. now owns 61,334 shares of the company’s stock worth $37,000 after purchasing an additional 39,101 shares in the last quarter. Palumbo Wealth Management LLC boosted its position in shares of Elevation Oncology by 294.5% during the 4th quarter. Palumbo Wealth Management LLC now owns 69,105 shares of the company’s stock worth $39,000 after purchasing an additional 51,590 shares in the last quarter. Barclays PLC increased its stake in Elevation Oncology by 302.4% during the 3rd quarter. Barclays PLC now owns 72,077 shares of the company’s stock valued at $43,000 after purchasing an additional 54,167 shares in the last quarter. Finally, GSA Capital Partners LLP purchased a new position in shares of Elevation Oncology during the third quarter valued at approximately $260,000. 83.70% of the stock is owned by institutional investors.

Elevation Oncology Company Profile

Elevation Oncology, Inc, an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target.